Adroit Lifescience Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 23-10-2024
- Paid Up Capital ₹ 0.20 M
as on 23-10-2024
- Company Age 14 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.50 M
as on 23-10-2024
- Revenue 6.62%
(FY 2023)
- Profit 83.47%
(FY 2023)
- Ebitda -228.17%
(FY 2023)
- Net Worth 68.34%
(FY 2023)
- Total Assets 11.40%
(FY 2023)
About Adroit Lifescience
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹3.50 M.
Snehangshu Dev and Jibika Sarma serve as directors at the Company.
- CIN/LLPIN
U24230GJ2010PTC062362
- Company No.
062362
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Sep 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Adroit Lifescience Private Limited offer?
Adroit Lifescience Private Limited offers a wide range of products and services, including Ayurveda Products, Natural Hair & Skin Care, Protein Supplements, Amino Acids, Skin Care, Sunscreen Products, Hair Care, Hair Growth for Men.
Who are the key members and board of directors at Adroit Lifescience?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Snehangshu Dev  | Director | 20-Sep-2010 | Current |
| Jibika Sarma | Director | 20-Sep-2010 | Current |
Financial Performance of Adroit Lifescience.
Adroit Lifescience Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 6.62% increase. The company also saw a substantial improvement in profitability, with a 83.47% increase in profit. The company's net worth Soared by an impressive increase of 68.34%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Adroit Lifescience?
In 2023, Adroit Lifescience had a promoter holding of 29.69% and a public holding of 70.31%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 09 Mar 2012 | ₹3.50 M | Open |
How Many Employees Work at Adroit Lifescience?
Adroit Lifescience has a workforce of 39 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Adroit Lifescience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Adroit Lifescience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
